January 30, 1991
Dr. Jerome P. Kassirer, a kidney disease specialist at Tufts University School of Medicine in Boston, has been selected as the new editor in chief of the New England Journal of Medicine, the Massachusetts Medical Society announced Tuesday. Kassirer, 58, will assume his new position, one of the most influential in American medicine, in July. He succeeds Dr. Arnold S. Relman, who will retire after 14 years as the journal's editor.
June 13, 2002 |
The New England Journal of Medicine is relaxing its strict conflict-of-interest rules for authors of certain articles because it cannot find enough experts without financial ties to drug companies. The change, announced in today's issue, applies to experts who write either editorials or review articles, which are overviews of research on a particular drug or treatment, rather than original studies. Dr. Jeffrey M.
June 10, 2005 |
Shares of Elan Corp. and Biogen Idec Inc. jumped Thursday after the New England Journal of Medicine published comments online that might suggest a way for Tysabri, the companies' troubled multiple sclerosis drug, to return to the market. Dublin, Ireland-based Elan's shares rose 77 cents to $7.37; Biogen closed up $1.78 at $35.13. Doctors at Biogen, based in Cambridge, Mass.
June 17, 1993 |
The New England Journal of Medicine, calling health care costs the "black hole of our economy," said the free market had created a non-system and threw its support behind global spending caps and an end to price competition. The journal proposed "a Canadian-style single-payer system to fund the delivery of health care," which it argued would be more efficient than the Administration goal of managed competition.
February 11, 2003 |
The New England Journal of Medicine retracted an article on a heart treatment Monday because one author had forged others' signatures on statements attesting that they had reviewed the data and the manuscript. "There was an egregious disregard of the principles of authorship," the journal's editor in chief, executive editor and managing editor wrote. The article, published in the journal Oct.
June 1, 2000 |
The newly appointed editor of the New England Journal of Medicine is pledging to divest any interest he has in pharmaceutical companies in an effort to avoid conflicts of interest. Dr. Jeffrey Drazen also said he might have made a mistake last year when he heaped praise on an asthma drug that was made by a company he was working for as a paid consultant. "We were probably a little overzealous," Drazen told the Boston Herald on Tuesday. "In the future, we'll be more careful."